IL266399B2 - Synthetic chimeric poxviruses, methods for producing same, compositions comprising same and uses thereof - Google Patents

Synthetic chimeric poxviruses, methods for producing same, compositions comprising same and uses thereof

Info

Publication number
IL266399B2
IL266399B2 IL266399A IL26639919A IL266399B2 IL 266399 B2 IL266399 B2 IL 266399B2 IL 266399 A IL266399 A IL 266399A IL 26639919 A IL26639919 A IL 26639919A IL 266399 B2 IL266399 B2 IL 266399B2
Authority
IL
Israel
Prior art keywords
virus
scopv
genome
vacv
schpxv
Prior art date
Application number
IL266399A
Other languages
English (en)
Hebrew (he)
Other versions
IL266399B1 (en
IL266399A (en
Original Assignee
Evans David
Noyce Ryan
Lederman Seth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evans David, Noyce Ryan, Lederman Seth filed Critical Evans David
Publication of IL266399A publication Critical patent/IL266399A/en
Publication of IL266399B1 publication Critical patent/IL266399B1/en
Publication of IL266399B2 publication Critical patent/IL266399B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL266399A 2016-11-02 2017-11-02 Synthetic chimeric poxviruses, methods for producing same, compositions comprising same and uses thereof IL266399B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416577P 2016-11-02 2016-11-02
US201662434794P 2016-12-15 2016-12-15
PCT/US2017/059782 WO2018085582A1 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses

Publications (3)

Publication Number Publication Date
IL266399A IL266399A (en) 2019-06-30
IL266399B1 IL266399B1 (en) 2025-05-01
IL266399B2 true IL266399B2 (en) 2025-09-01

Family

ID=62075555

Family Applications (2)

Application Number Title Priority Date Filing Date
IL266399A IL266399B2 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses, methods for producing same, compositions comprising same and uses thereof
IL319942A IL319942A (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL319942A IL319942A (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof

Country Status (13)

Country Link
US (3) US11345896B2 (https=)
EP (1) EP3535389A4 (https=)
JP (3) JP2019535311A (https=)
CN (1) CN110431228B (https=)
AU (2) AU2017353868C1 (https=)
BR (1) BR112019008781A2 (https=)
CA (1) CA3042694A1 (https=)
IL (2) IL266399B2 (https=)
MX (1) MX2019005102A (https=)
SG (1) SG11201903893PA (https=)
TW (2) TW202528334A (https=)
WO (1) WO2018085582A1 (https=)
ZA (3) ZA201902868B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535311A (ja) 2016-11-02 2019-12-12 デイビッド エバンス， 合成キメラポックスウイルス
US20180228921A1 (en) * 2017-02-13 2018-08-16 Excision Biotherapeutics, Inc. Visualizing viral reservoirs and dissemination in vivo
EP3788142A4 (en) * 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS
US20240024393A1 (en) * 2019-01-25 2024-01-25 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus
US20230097513A1 (en) * 2020-02-03 2023-03-30 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
KR20220165731A (ko) * 2020-02-26 2022-12-15 토닉스 파마 리미티드 Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
JP2024505274A (ja) 2021-02-02 2024-02-05 ゲオバックス インコーポレイテッド ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
WO2005028634A2 (en) 2003-09-18 2005-03-31 Emory University Improved mva vaccines
JPWO2006022215A1 (ja) 2004-08-23 2008-05-08 財団法人ヒューマンサイエンス振興財団 ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
WO2014166084A1 (en) 2013-04-10 2014-10-16 Totbiopharm Shanghai R & D Center Mutant vaccinia virus strains, uses thereof and method of producing the same
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
CN108135996B (zh) 2015-08-11 2022-06-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
AU2017332367B2 (en) 2016-09-21 2021-12-23 Stephen H. Thorne High mobility group box i mutant
JP2019535311A (ja) 2016-11-02 2019-12-12 デイビッド エバンス， 合成キメラポックスウイルス
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
CN112261951A (zh) 2018-05-02 2021-01-22 通尼克斯制药控股有限公司 包含合成嵌合痘苗病毒的干细胞及其使用方法
EP3788142A4 (en) 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. R. TULMAN ET AL,, GENOME OF HORSEPOX VIRUS, 15 September 2006 (2006-09-15) *

Also Published As

Publication number Publication date
AU2017353868B2 (en) 2024-02-29
MX2019005102A (es) 2019-10-30
US20230002741A1 (en) 2023-01-05
IL266399B1 (en) 2025-05-01
TW202528334A (zh) 2025-07-16
IL319942A (en) 2025-05-01
US11345896B2 (en) 2022-05-31
TW201819400A (zh) 2018-06-01
ZA202204981B (en) 2024-09-25
JP2022164900A (ja) 2022-10-27
IL266399A (en) 2019-06-30
AU2024200997A1 (en) 2024-03-07
EP3535389A1 (en) 2019-09-11
US20180251736A1 (en) 2018-09-06
JP2019535311A (ja) 2019-12-12
TWI887191B (zh) 2025-06-21
AU2017353868A1 (en) 2019-05-16
CN110431228B (zh) 2024-04-02
BR112019008781A2 (pt) 2019-07-16
US12365879B2 (en) 2025-07-22
AU2017353868C1 (en) 2024-06-06
ZA202403393B (en) 2025-08-27
CN110431228A (zh) 2019-11-08
WO2018085582A1 (en) 2018-05-11
ZA201902868B (en) 2022-12-21
US20260022350A1 (en) 2026-01-22
NZ752893A (en) 2025-10-31
SG11201903893PA (en) 2019-05-30
CA3042694A1 (en) 2018-05-11
JP2024107257A (ja) 2024-08-08
EP3535389A4 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
US12365879B2 (en) Synthetic chimeric poxviruses
US12529036B2 (en) Synthetic chimeric vaccinia virus
IL295925A (en) A vaccine based on the recombinant pox virus against 2-cov-sars
JP2024138521A (ja) 複製効率の高い免疫調節ワクシニアウイルス株
US20210236619A1 (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
US20040014034A1 (en) Method of producing a recombinant virus
HK40014109A (en) Synthetic chimeric poxviruses
HK40014109B (zh) 合成嵌合痘病毒
Holley Mechanistic Constraints on the Formation of Virion Morphotypes in Vaccinia Virus
Ríos et al. INVESTIGATION OF POXVIRUS HOST-RANGE AND GENE EXPRESSION IN MAMMALIAN CELLS.